| Entry |
|
|---|
| Name |
Peginterferon alfa-2b (USAN/INN);
Peginterferon alfa-2b (genetical recombination) (JAN);
Pegintron (TN);
Sylatron (TN) |
|---|
| Formula |
C2H3O2R(C2H4O)n
|
|---|
| Structure |
|
|---|
| Sequence |
CDLPQTHSLG SRRTLMLLAQ MRRISLFSCL KDRHDFGFPQ EEFGNQFQKA ETIPVLHEMI
QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI QGVGVTETPL MKEDSILAVR
KYFQRITLYL KEKKYSPCAW EVVRAEIMRS FSLSTNLQES LRSKE
(Disulfide bridge: 1-98, 29-138; Pegylation site: 1, 31, 121, 134) |
|---|
| Type |
Peptide |
|---|
| Class |
Immunological agent
DG01752 Interferone
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
DG01645 CYP2D6 inhibitor
|
|---|
| Remark |
|
|---|
| Efficacy |
Antiviral, Biological response modifier |
|---|
| Disease |
|
|---|
| Comment |
R: Interferon alfa-2b [DR: D02745]
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04060 | Cytokine-cytokine receptor interaction |
| hsa04620 | Toll-like receptor signaling pathway |
| hsa04650 | Natural killer cell mediated cytotoxicity |
|
|---|
| Interaction |
CYP inhibition: CYP1A2 [HSA: 1544], CYP2D6 [HSA: 1565]
|
|---|
| Structure map |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L03 IMMUNOSTIMULANTS
L03A IMMUNOSTIMULANTS
L03AB Interferons
L03AB10 Peginterferon alfa-2b
D02748 Peginterferon alfa-2b (USAN/INN)
USP drug classification [BR:br08302]
Immunological Agents
Immunostimulants
Interferons
Peginterferon Alfa-2b
D02748 Peginterferon alfa-2b (USAN/INN)
Drug groups [BR:br08330]
Immunological agent
DG01752 Interferone
D02748 Peginterferon alfa-2b
Metabolizing enzyme inhibitor
DG01634 CYP1A2 inhibitor
D02748 Peginterferon alfa-2b
DG01645 CYP2D6 inhibitor
D02748 Peginterferon alfa-2b
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
Interferon receptors
IFNAR1
D02748 Peginterferon alfa-2b (USAN/INN)
IFNAR2
D02748 Peginterferon alfa-2b (USAN/INN)
Antimicrobials [BR:br08307]
Antivirals
Entry, fusion or uncoating inhibitor
Interferon
D02748 Peginterferon alfa-2b (USAN/INN)
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D02748
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D02748
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D02748
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D02748
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 8
1 C7a C 23.8000 -25.4800
2 R R 25.0124 -26.1800
3 O7a O 22.5876 -26.1800
4 O6a O 23.8000 -24.0800
5 C1b C 21.3921 -25.4896
6 C1b C 20.2047 -26.1751
7 O2a O 19.0135 -25.4871
8 C1a C 17.8240 -26.1738
BOND 7
1 1 2 1
2 1 3 1
3 1 4 2
4 3 5 1
5 5 6 1
6 6 7 1
7 7 8 1
BRACKET 1 18.6900 -27.1600 18.6900 -25.0600
1 21.5600 -25.0600 21.5600 -27.1600
1 n
ORIGINAL 1 5 6 7
REPEAT 1
|
|---|
